Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Bris­tol My­ers Squibb is ax­ing a Phase III tri­al in­ves­ti­gat­ing its com­bi­na­tion of nivolum­ab (Op­di­vo) and re­latlimab in col­orec­tal can­cer af­ter a da­ta mon­i­tor­ing com­mit­tee said it was “un­like­ly” to meet the pri­ma­ry end­points, the com­pa­ny said Fri­day.

In the Phase III REL­A­TIV­I­TY-123 study, BMS was in­ves­ti­gat­ing nivolum­ab plus re­latlimab in pa­tients with mi­crosatel­lite sta­ble metasta­t­ic col­orec­tal can­cer (mCRC) whose dis­ease has pro­gressed fol­low­ing at least one, though no more than four, pri­or lines of treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER